Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. develops clinical-stage, oncology-focused antibody therapeutics targeting angiogenesis, immune activation and tumor-driven immunosuppression. News about CMPX centers on its antibody pipeline, including tovecimig, a DLL4 x VEGF-A bispecific antibody studied with paclitaxel in biliary tract cancer, and earlier-stage programs such as CTX-8371, CTX-10726 and CTX-471.
Recurring updates cover clinical trial results, FDA-related regulatory designations and interactions, medical-meeting presentations, pipeline expansion, financial results, cash resources, leadership changes and equity inducement grants under Nasdaq rules.
Compass Therapeutics (Nasdaq:CMPX) will participate in two May 2026 investor conferences focused on biotechnology and oncology.
The company presents at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on May 19 at 1:30 PM ET, and at the 2026 Stifel Virtual Targeted Oncology Forum on May 20 at 11:30 AM ET. Both presentations are accessible via webcast, with replays available on the company’s Events page. Management will be available for one-on-one investor meetings arranged through conference representatives.
Compass Therapeutics (Nasdaq: CMPX) reported Q1 2026 results and a corporate update on May 5, 2026. Key clinical highlights include positive Phase 2/3 data for tovecimig (ORR 17.1% vs 5.3%, PFS 4.7 vs 2.6 months, HR=0.44, p<0.0001) and FDA Orphan Drug designation; company plans a pre-BLA meeting and a BLA later this year. CTX-8371 cohort expansions and an ASCO 2026 poster were announced; CTX-10726 Phase 1 initiated with initial data expected in Q4 2026. Financials: net loss $18.3M; cash and marketable securities $195M, runway into 2028.
Compass Therapeutics (Nasdaq: CMPX) reported COMPANION-002 results showing tovecimig plus paclitaxel met key secondary PFS and primary ORR endpoints in second-line biliary tract cancer. Median PFS was 4.7 vs 2.6 months (HR=0.44, p<0.0001). ORR was 17.1% vs 5.3% (p=0.031). OS was confounded by 54% crossover; pooled median OS was 8.9 months. Safety: hypertension and neutropenia were notable. Company plans an FDA meeting ahead of a planned BLA and will present full data at a medical conference.
Compass Therapeutics (Nasdaq: CMPX) will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 study of tovecimig (a DLL4 x VEGF-A bispecific antibody) plus paclitaxel in advanced biliary tract cancer.
Dial-in numbers and a webcast URL are provided; a replay and accompanying presentation will be available for 90 days on the company’s Investors Events page.
Compass Therapeutics (Nasdaq: CMPX) reported 2025 results and a corporate update on March 5, 2026. Key clinical milestones include tovecimig meeting the primary ORR endpoint in COMPANION-002 and planned PFS/OS analyses in April 2026. CTX-8371 expansion cohorts for TNBC and NSCLC are open; an HL cohort will be added. The IND for CTX-10726 was cleared and Phase 1 will open in Q1 2026. Leadership changes include promotion of Bing Gong to CSO and new CMO/CCO hires. Cash and marketable securities were $209 million at year-end 2025, with runway into 2028.
Compass Therapeutics (NASDAQ: CMPX) provided a corporate update on January 6, 2026, reporting pipeline progress, leadership hires, upcoming data readouts, and a cash position. Key items include PFS and OS analyses for tovecimig on track for late Q1 2026, a planned Phase 2 DLL4+ basket study following COMPANION-002 analysis, and a 5% ORR (2/40) for tovecimig monotherapy in heavily pretreated colorectal cancer (all had prior bevacizumab).
For CTX-8371, cohort expansions in TNBC and NSCLC (n=28 each) are open with dose levels 3.0 and 10.0 mg/kg; a third confirmed response in Hodgkin lymphoma was reported. CTX-10726 Phase 1 is expected to start in Q1 2026. Estimated cash and marketable securities were $209 million as of December 31, 2025, providing runway into 2028.
Compass Therapeutics (Nasdaq: CMPX) granted inducement stock options to two newly appointed executives under its 2025 Inducement Plan on January 5, 2026.
The company awarded 1,000,000 non‑qualified stock options to Chief Commercial Officer Arjun Prasad and 1,000,000 to Chief Medical Officer Cynthia Sirard, each with an exercise price of $5.17 (closing price on January 2, 2026). The options carry a 10‑year term and vest over four years (25% after one year, then 36 monthly installments). Grants were approved by the Compensation Committee and made as material inducements under Nasdaq Rule 5635(c)(4).
Compass Therapeutics (Nasdaq: CMPX) announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, effective January 1, 2026.
Mr. Prasad joins from Servier Pharmaceuticals and has led >10 oncology launches including the 2024 launch of VORANIGO and commercialization of TIBSOVO for biliary tract cancer. Dr. Sirard joins from Leap Therapeutics with prior leadership at Sanofi and Genzyme, and has guided programs through IND filings, clinical development, pivotal trials, and regulatory approval. Management says these hires strengthen Compass’s ability to advance tovecimig and its oncology pipeline.
Compass Therapeutics (Nasdaq: CMPX) will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. The presentation is scheduled for 7:30 AM PT and will be webcast at cmpx.info/jpmorgan.
Virtual replay and an archived copy will be available on Compass’ Events page. Compass is also hosting investor meetings as part of the LifeSci Partners Corporate Access Event on January 12–13, 2026 in San Francisco. Investors seeking one-on-one meetings should contact their J.P. Morgan or LifeSci representative to request meetings.
Compass Therapeutics (Nasdaq: CMPX) will participate in two investor events in December 2025: the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 8:00 AM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 4, 2025 at 10:00 AM ET.
Live webcasts are provided for each presentation and recordings will be archived for 90 days on Compass’ Events page. Management will be available for one-on-one meetings during both events; interested investors should contact their representatives to request meetings.